• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Akumin Provides Business Update and Announces CFO Transition

    8/12/22 5:56:00 PM ET
    $AKU
    $ELV
    $SGRY
    Medical Specialities
    Health Care
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today.

    The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the Company announced: (a) the termination of employment of its Chief Financial Officer, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as Interim Chief Financial Officer, effective today; and (b) the sale of certain accounts receivables by subsidiaries of the Company to a third-party buyer for a purchase price of approximately $30 million.

    Riadh Zine, Chairman and Chief Executive Officer of Akumin, commented: "Our transformation efforts to date have already resulted in significant efficiencies to our operations and show a positive momentum for further efficiencies, as discussed in our second quarter results.  I am very excited to welcome David as our new Interim Chief Financial Officer. We are thrilled to have his expertise complement our team as we successfully execute our transformation program. On behalf of the board of directors of Akumin, I would also like to thank Bill for his contributions to the Company and wish him the very best in his next endeavors."

    Mr. Zine continued: "The sale of certain accounts receivables has significantly improved the liquidity of our Company by an immediate cash infusion of approximately $30 million and a reduction in our days sales outstanding of our accounts receivables. Our cash position at the end of the second quarter of 2022 pro forma this sale would have been approximately $69 million. In addition, any future sale of similar accounts receivables in the normal course of business would not be expected to have any material impact on our revenues."

    Before joining the Company, Mr. Kretschmer previously worked for Surgery Partners, Inc. (NASDAQ:SGRY), a multi-specialty ambulatory surgical center company with $2.5 billion of revenues, as interim CFO and executive vice president of strategy and transformation, and, prior to that, as senior vice president, treasurer and CIO for Anthem, Inc. renamed Elevance Health, Inc. (NASDAQ:ELV), a health insurance provider with more than $130 billion of revenues, and he was a key team member in the execution of the successful business transformation of each of these companies.

    About Akumin

    Akumin is a national leader in comprehensive outpatient radiology and oncology solutions and a partner of choice for U.S. hospitals, health systems and physician groups. Akumin provides fixed-site outpatient radiology and oncology services through a network of 234 owned and/or operated centers; as well as outpatient radiology and oncology solutions to approximately 1,000 hospitals and health systems across 48 states. Akumin combines clinical and operational expertise with the latest advances in technology and information systems to deliver patient-centered innovation, service standardization and exceptional healthcare value to its patients and partners. For more information, visit www.akumin.com.

    Forward-Looking Information

    Certain information in this press release constitutes forward-looking information or forward-looking statements. In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

    Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the factors described in greater detail in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended June 30, 2022, filed with the SEC on August 9, 2022,  which is available at www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

    Cision View original content:https://www.prnewswire.com/news-releases/akumin-provides-business-update-and-announces-cfo-transition-301605278.html

    SOURCE Akumin Inc.

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $ELV
    $SGRY

    CompanyDatePrice TargetRatingAnalyst
    Elevance Health Inc.
    $ELV
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    Elevance Health Inc.
    $ELV
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    Elevance Health Inc.
    $ELV
    4/8/2026$345.00In-line
    Evercore ISI
    Elevance Health Inc.
    $ELV
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    Elevance Health Inc.
    $ELV
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    Elevance Health Inc.
    $ELV
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    Elevance Health Inc.
    $ELV
    10/14/2025Neutral
    Goldman
    Surgery Partners Inc.
    $SGRY
    9/18/2025$27.00Neutral
    Analyst
    More analyst ratings

    $AKU
    $ELV
    $SGRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    SEC Filings

    View All

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 11:27:18 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 6:01:33 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Hendrix Blair E was granted 34,364 shares, increasing direct ownership by 185% to 52,895 units (SEC Form 4)

    4 - Surgery Partners, Inc. (0001638833) (Issuer)

    7/14/26 5:07:25 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $AKU
    $ELV
    $SGRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surgery Partners Inc.

    SC 13G/A - Surgery Partners, Inc. (0001638833) (Subject)

    11/8/24 10:46:38 AM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Surgery Partners Inc.

    SC 13G - Surgery Partners, Inc. (0001638833) (Subject)

    10/24/24 2:02:10 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $AKU
    $ELV
    $SGRY
    Leadership Updates

    Live Leadership Updates

    View All

    Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

    BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company") recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors. Mr. Dean is the former Chief Executive Officer of CommonSpirit Health, one of the largest nonprofit health systems in the United States, with 142 hospitals, over 1,000 care sites, 25,000 physicians, and 150,000 employees across 21 states. From 2019 to 2022, he led the formation and integration of CommonSpirit, advancing clinical quality, operational performance, and community health initiatives at national scale. Prior to CommonSpirit, Mr. Dean ser

    3/12/26 6:12:07 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $AKU
    $ELV
    $SGRY
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance

    BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 4.5% for the first quarter Same-facility revenues increased 4.4% for the first quarterSame-facility cases increased 0.6% for the first quarter Net loss attributable to Surgery Partners, Inc. was $35.9 million for the first quarter Adjusted EBITDA was $102.3 million for the first quarter 2026 Guidance

    5/5/26 7:30:00 AM ET
    $SGRY
    Hospital/Nursing Management
    Health Care